Text Size
S
M
L
Listen
Santen Global
menu
Patients
Healthcare Professionals
Careers
Investors
Listen
Tap on the left to use.
Who We Are
Message
Message from the CEO
Santen’s Corporate Philosophy Framework
Santen’s Corporate Philosophy Framework
History
History of Santen
Corporate Executives
Corporate Executives
Corporate Governance
Corporate Governance
Digital Transformation
Digital Transformation
Policies
Policies and Statements
Company Infomation
Overview / Map
Global Operation
What We Do
MTP
Medium-term Management Plan
Efforts to Enhance Patients' Satisfaction
Efforts to Enhance Product Usability
Efforts to Address Untreated Patients
Research & Development
Research & Development
The Ophthalmic Development Process
Clinical Trial Information
Partnering
Santen's Partnership
Our Partners
Partnering Contact
Production
Production
Safety and Quality Assurance
The Ophthalmic Production Process
Our Stories
Sustainability
Sustainability
Our Sustainability Commitment
Sustainability at Santen
Social
Access to Healthcare
Research & Development in Ophthalmology
Product Quality & Safety
Supply Chain
Human Rights
Talent
Governance
Corporate Governance
Compliance
Ethical Marketing
Risk Management
Information Security
Environment
Environmental initiatives
Measures against Climate Change
Environmental Load Reduction
Biodiversity
Disclosures Based on the TCFD Recommendations
Inclusion
Inclusive Society Santen Promotes
Inclusion Starting from Blind Football
Together with Society
With Employees
Related Information
Participating in the UN Global Compact
Social Contribution Activities
Stakeholder Engagement
Environment Data (up-to-date)
Social Data (up-to-date)
Governance Data (up-to-date)
GRI Standards Content Index
Sustainability Library
External Assessment
News
News
Show All
Press Release
IR News
Information
HOME
News
News
Press Release
IR News
Information
Press Release
06.05.2025
European Commission Approves Santen’s Ryjunea® to Slow Progression of Paediatric Myopia
05.21.2025
Santen and Bayer Yakuhin Launch New Pre-Filled Syringe for EYLEA® 8 mg, EYLEA® 8 mg intraocular injection kit 114.3 mg/mL
05.21.2025
Santen Announces FY2025-2029 Medium-Term Management Plan
05.01.2025
Notice of Board of Director and Corporate Auditor Nominations
04.04.2025
Santen Announces China NMPA Approval of Tapcom🄬 in Patients with Open-Angle Glaucoma or Ocular Hypertension
Press Release
IR News
07.01.2025
Corporate Governance Report
07.01.2025
Santen Announces Status of Share Buyback
06.05.2025
European Commission Approves Santen’s Ryjunea® to Slow Progression of Paediatric Myopia
06.02.2025
Santen Announces Status of Share Buyback
05.21.2025
Santen and Bayer Yakuhin Launch New Pre-Filled Syringe for EYLEA® 8 mg, EYLEA® 8 mg intraocular injection kit 114.3 mg/mL
IR News
Information
06.09.2025
Santen joins Mainichi Shimbun’s Vision Consortium
05.30.2025
Santen Signs the Joint Policy Statement on Protecting Children’s Vision in the Digital Age in Europe
10.01.2024
Santen Providing Disaster Relief to Communities Impacted by Heavy Rain in Noto Peninsula
08.05.2024
Cutting Back on Pouches and Medicine Bags Provided With Eye Drops -Santen’s Efforts to Reduce Single-Use Plastic to Decrease Our Environmental Footprint-
05.21.2024
Santen Recognized for Longstanding Commitment to Nippon Lighthouse Guide Dog Training Program
Information
News Archive
